Investigation of the Acute and Chronic Cognitive and Mood Effects of CP9700 in Humans

This acute-on-chronic study will examine the effectiveness of CP9700 for improving cognitive performance and mood in healthy young adults. CP9700 is a mix of highly purified grape seed-derived polyphenolic extracts from Vitis vinifera produced by Polyphenolics Inc. (Madera, CA, USA). The polyphenolic component of the product is comprised entirely of catechin and epicatechin, derivatives of catechin and epicatechin (e.g.,epicatechin gallate), and proanthocyanidins. We will perform a randomised, double-blind, parallel-groups human intervention trial using CP9700 and a well characterised sugar-matched placebo to investigate changes in cognitive performance.

Study Overview

• Status: Completed
• Conditions: Cognitive Function; Mood
• Intervention / Treatment: Dietary supplement: CP9700; Dietary supplement: Matched Placebo

Detailed Description

Interventions: Two interventions will be tested, CP9700 (400 mg) and a placebo. Importantly, the placebo will be matched to the active treatment for sugars and vitamin C levels. All interventions will be supplied in blister packs.

Participants: A total of 60 healthy, young adult participants will be recruited for these studies. Based upon the medium effect size (d = .65) observed in previous work using healthy adults and the Go/No go task, we calculate that a sample of 25 participants/treatment will provide considerable power (.70) to detect a similar sized effect in this study. The recruitment procedure allows for a 15% drop out rate. Participants will be recruited directly from the School of Psychology & Clinical Language Sciences Undergraduate Research Panel.

Procedure: Following recruitment to the study, participants will start a two-week 'run-in' phase. During this phase, all participants will complete a 3-day food frequency questionnaire to give a measure of their habitual diet before being asked to adhere to a low-flavonoid diet, we will collect a 3-day food diary to check compliance and they will attend the laboratory for an initial 'practice' session of the cognitive tasks (see below). On the evening before the 'active treatment' phase commences, participants will be asked to consume a standard meal- this procedure will be repeated for each evening meal consumed prior to a test day. On the acute test day, participants will attend the laboratory in a fasted state where they will receive a standard low-flavanoid breakfast, followed by a battery of cognitive and mood tasks (see below). Subjects will then be given their intervention, and will be re-tested on our task battery at two-hourly intervals over a 6 hour period before being allowed to return home. During the chronic phase of the study, after 6 and 12 weeks of consuming the intervention, subjects will return to the lab in a fasted state (prior to taking their daily intervention), will be given a standard low flavonoid breakfast, and will be tested on the task battery before consuming their allocated intervention. Compliance will be assured through collection of used blister packs.

The task battery is composed of cognitive tests and measures of mood, which our previous data show to be sensitive to flavonoid interventions, both acutely and chronically. More generally, the cognitive tests are categorised into one of two key cognitive domains; (i) Executive Function (i.e., Serial Sevens, Stroop, Modified Attention Network Test) and (ii) Episodic Memory (i.e., immediate and delayed auditory recall, verbal recognition, immediate and delayed spatial memory). Moreover, our previous data indicates increased cerebral blood flow in the in the acute postprandial phase 2-5 hours following flavonoid consumption in brain regions required for executive function and episodic memory including the frontal cortex and frontal gyrus. In addition, changes in mood will be measured using the PANAS, which has previously been shown to be sensitive to flavonoid interventions acutely and chronically.

• Study Type: Interventional
• Enrollment (Actual): 60
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United Kingdom
  • Berkshire
    • Reading, Berkshire, United Kingdom, RG6 6AL
      • University of Reading

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years to 30 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Non Smoker
• Not Pregnant
• Non vegetarian or vegan
• Able to consume the capsules

Exclusion Criteria:

• Should not suffer from any of the following diseases: Major mental illness; Liver disease; Diabetes mellitus (Type 1 and 2); Heart disease; Renal or gastrointestinal disorders
• Should not be taking blood pressure lowering or anticoagulant medication
• Should not be taking depression medication
• Should not be consuming more than the Government recommended units of alcohol per week
• Should not be vigorous exercisers (restricted to < 4 hours per week for the duration of the study)
• Should not be taking nutritional supplements (for the duration of the study)
• Should not be taking recreational drugs (either illegal or legal for the duration of the study)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: CP9700; 400 mg CP9700 along with modified cellulose (MCC), magnesium stearate, silica (sillicon dioxide), Gelatin, FD&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.	Dietary supplement: CP9700; 400 mg CP9700 along with modified cellulose (MCC), magnesioum strearate, slica (sillicon dioxide), Gelatin, FD&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
Placebo Comparator: Matched Placebo; Maltodextrin along with modified cellulose (MCC), magnesium stearate, silica (sillicon dioxide), Gelatin, FD&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.	Dietary supplement: Matched Placebo; Maltodextrin along with modified cellulose (MCC), magnesioum strearate, slica (sillicon dioxide), Gelatin, FD&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cognitive Performance - Episodic Memory	As Measured by the Auditory Verbal Learning Task	2 hrs following acute intervention.
Cognitive Performance - Episodic Memory	As Measured by the Auditory Verbal Learning Task	4 hrs following acute intervention.
Cognitive Performance - Episodic Memory	As Measured by the Auditory Verbal Learning Task	6 hrs following acute intervention.
Cognitive Performance - Episodic Memory	As Measured by the Auditory Verbal Learning Task	Following 6 weeks chronic intervention
Cognitive Performance - Episodic Memory	As Measured by the Auditory Verbal Learning Task	Following 12 weeks chronic intervention
Cognitive Performance - Attention shifting	As measured by the Switching Task	2 hrs following acute intervention.
Cognitive Performance - Attention shifting	As measured by the Switching Task	4 hrs following acute intervention.
Cognitive Performance - Attention shifting	As measured by the Switching Task	6 hrs following acute intervention.
Cognitive Performance - Attention shifting	As measured by the Switching Task	Following 6 weeks chronic intervention
Cognitive Performance - Attention shifting	As measured by the Switching Task	Following 12 weeks chronic intervention
Cognitive Performance - Motor Control	As measured by the finger tapping task	2 hrs following acute intervention.
Cognitive Performance - Motor Control	As measured by the finger tapping task	4 hrs following acute intervention.
Cognitive Performance - Motor Control	As measured by the finger tapping task	6 hrs following acute intervention.
Cognitive Performance - Motor Control	As measured by the finger tapping task	Following 6 weeks chronic intervention
Cognitive Performance - Motor Control	As measured by the finger tapping task	Following 12 weeks chronic intervention
Cognitive Performance - Working Memory	As measured by the serial 3 and 7s task	2 hrs following acute intervention.
Cognitive Performance - Working Memory	As measured by the serial 3 and 7s task	4 hrs following acute intervention.
Cognitive Performance - Working Memory	As measured by the serial 3 and 7s task	6 hrs following acute intervention.
Cognitive Performance - Working Memory	As measured by the serial 3 and 7s task	Following 6 weeks chronic intervention
Cognitive Performance - Working Memory	As measured by the serial 3 and 7s task	Following 12 weeks chronic intervention
Cognitive Performance - Visual Memory Span	As measured by the Corsi Block Task	2 hrs following acute intervention.
Cognitive Performance - Visual Memory Span	As measured by the Corsi Block Task	4 hrs following acute intervention.
Cognitive Performance - Visual Memory Span	As measured by the Corsi Block Task	6 hrs following acute intervention.
Cognitive Performance - Visual Memory Span	As measured by the Corsi Block Task	Following 6 weeks chronic intervention
Cognitive Performance - Visual Memory Span	As measured by the Corsi Block Task	Following 12 weeks chronic intervention

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mood	As measured by the Positive and Negative Affect Schedule	2 hrs following acute intervention.
Mood	As measured by the Positive and Negative Affect Schedule	4 hrs following acute intervention.
Mood	As measured by the Positive and Negative Affect Schedule	6 hrs following acute intervention.
Mood	As measured by the Positive and Negative Affect Schedule	Following 6 weeks chronic intervention
Mood	As measured by the Positive and Negative Affect Schedule	Following 12 weeks chronic intervention

Collaborators and Investigators

• Sponsor: University of Reading
• Collaborators: Polyphenolics, Inc.
• Investigators: Principal Investigator: Claire M Williams, PhD, University of Reading

Publications and helpful links

General Publications

• Macready AL, Kennedy OB, Ellis JA, Williams CM, Spencer JP, Butler LT. Flavonoids and cognitive function: a review of human randomized controlled trial studies and recommendations for future studies. Genes Nutr. 2009 Dec;4(4):227-42. doi: 10.1007/s12263-009-0135-4. Epub 2009 Aug 13.
• Bell L, Lamport DJ, Butler LT, Williams CM. A Review of the Cognitive Effects Observed in Humans Following Acute Supplementation with Flavonoids, and Their Associated Mechanisms of Action. Nutrients. 2015 Dec 9;7(12):10290-306. doi: 10.3390/nu7125538.
• Lamport DJ, Dye L, Wightman JD, Lawton CL. A. The effects of flavonoid and other polyphenol consumption on cognitive performance: A systematic research review of human experimental and epidemiological studies. Nutrition and Aging. 1(1), 5-25, 2012

Study record dates

Study Major Dates

• Study Start (Actual): November 20, 2017
• Primary Completion (Actual): February 28, 2019
• Study Completion (Actual): February 28, 2019

Study Registration Dates

• First Submitted: November 14, 2017
• First Submitted That Met QC Criteria: May 3, 2018
• First Posted (Actual): May 16, 2018

Study Record Updates

• Last Update Posted (Actual): August 20, 2020
• Last Update Submitted That Met QC Criteria: August 19, 2020
• Last Verified: August 1, 2020

More Information

Terms related to this study

• Keywords: Cognition; Mood; Epicatechin; Flavonoid; Grape Seed; Catechin; Proanthocyanidin
• Other Study ID Numbers: RDG-003

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No